State Street SPDR S&P Pharmaceuticals ETF
XPH
92 hedge funds and large institutions have $265M invested in State Street SPDR S&P Pharmaceuticals ETF in 2026 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 25 increasing their positions, 29 reducing their positions, and 8 closing their positions.
163% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 8
13% more capital invested
Capital invested by funds: $235M → $265M (+$30M)
11% more funds holding
Funds holding: 83 → 92 (+9)
12.11% less ownership
Funds ownership: 76.26% → 64.15% (-12%)
14% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 29
32% less call options, than puts
Call options by funds: $1.39M | Put options by funds: $2.05M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$11.9M |
| 2 |
MWPCG
Measured Wealth Private Client Group
Portsmouth,
New Hampshire
|
+$4M |
| 3 |
Citigroup
New York
|
+$3.21M |
| 4 |
Morgan Stanley
New York
|
+$1.56M |
| 5 |
LPL Financial
San Diego,
California
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$2.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.21M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.1M |
| 4 |
Jane Street
New York
|
-$999K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$993K |
XPH Hedge Fund Activity: Q2 2026 in Review
92 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2026, worth a combined $265M — up 13% from $235M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new XPH positions and 8 closed out — a net gain of 13 holders — while 25 added to existing stakes and 29 trimmed.
The largest buyer was Bank of America, adding an estimated $11.9M. The largest seller was Envestnet Asset Management, cutting an estimated $2.9M.
- 92 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2026, up from 83 in Q1 2026.
- Funds reported $265M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2026, up 13% quarter-over-quarter.
- 21 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2026 and 8 closed out, a net change of +13 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q2 2026 was Bank of America, an estimated $11.9M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q2 2026 was Envestnet Asset Management, an estimated $2.9M sold.
Based on aggregated 13F filings for Q2 2026.